219 related articles for article (PubMed ID: 18062731)
1. Utilization, cost trends, and member cost-share for self-injectable multiple sclerosis drugs--pharmacy and medical benefit spending from 2004 through 2007.
Kunze AM; Gunderson BW; Gleason PP; Heaton AH; Johnson SV
J Manag Care Pharm; 2007; 13(9):799-806. PubMed ID: 18062731
[TBL] [Abstract][Full Text] [Related]
2. Five-year examination of utilization and drug cost outcomes associated with benefit design changes including reference pricing for proton pump inhibitors in a state employee health plan.
Johnson JT; Neill KK; Davis DA
J Manag Care Pharm; 2011 Apr; 17(3):200-12. PubMed ID: 21434697
[TBL] [Abstract][Full Text] [Related]
3. Effect on drug utilization and expenditures of a cost-share change from copayment to coinsurance.
Klepser DG; Huether JR; Handke LJ; Williams CE
J Manag Care Pharm; 2007; 13(9):765-77. PubMed ID: 18062728
[TBL] [Abstract][Full Text] [Related]
4. Pharmacy benefit spending on oral chemotherapy drugs.
Curtiss FR
J Manag Care Pharm; 2006 Sep; 12(7):570-7. PubMed ID: 16981802
[TBL] [Abstract][Full Text] [Related]
5. Association of prescription abandonment with cost share for high-cost specialty pharmacy medications.
Gleason PP; Starner CI; Gunderson BW; Schafer JA; Sarran HS
J Manag Care Pharm; 2009 Oct; 15(8):648-58. PubMed ID: 19803554
[TBL] [Abstract][Full Text] [Related]
6. Comparison of mail-order with community pharmacy in plan sponsor cost and member cost in two large pharmacy benefit plans.
Johnsrud M; Lawson KA; Shepherd MD
J Manag Care Pharm; 2007 Mar; 13(2):122-34. PubMed ID: 17330973
[TBL] [Abstract][Full Text] [Related]
7. Descriptive analysis of the direct medical costs of multiple sclerosis in 2004 using administrative claims in a large nationwide database.
Prescott JD; Factor S; Pill M; Levi GW
J Manag Care Pharm; 2007; 13(1):44-52. PubMed ID: 17269836
[TBL] [Abstract][Full Text] [Related]
8. All-cause health care utilization and costs associated with newly diagnosed multiple sclerosis in the United States.
Asche CV; Singer ME; Jhaveri M; Chung H; Miller A
J Manag Care Pharm; 2010; 16(9):703-12. PubMed ID: 21067256
[TBL] [Abstract][Full Text] [Related]
9. Cost and utilization of behavioral health medications associated with rescission of an exemption for prior authorization for severe and persistent mental illness in the Vermont Medicaid Program.
Simeone JC; Marcoux RM; Quilliam BJ
J Manag Care Pharm; 2010 Jun; 16(5):317-28. PubMed ID: 20518584
[TBL] [Abstract][Full Text] [Related]
10. Health plan utilization and costs of specialty drugs within 4 chronic conditions.
Gleason PP; Alexander GC; Starner CI; Ritter ST; Van Houten HK; Gunderson BW; Shah ND
J Manag Care Pharm; 2013 Sep; 19(7):542-8. PubMed ID: 23964615
[TBL] [Abstract][Full Text] [Related]
11. Cost effectiveness and budget impact of natalizumab in patients with relapsing multiple sclerosis.
Chiao E; Meyer K
Curr Med Res Opin; 2009 Jun; 25(6):1445-54. PubMed ID: 19422279
[TBL] [Abstract][Full Text] [Related]
12. New FDA-Approved Disease-Modifying Therapies for Multiple Sclerosis.
English C; Aloi JJ
Clin Ther; 2015 Apr; 37(4):691-715. PubMed ID: 25846320
[TBL] [Abstract][Full Text] [Related]
13. Relationship of the use and costs of physician office visits and prescription drugs to travel distance and increases in member cost share.
Cecil WT; Barnes J; Shea T; Coulter SL
J Manag Care Pharm; 2006 Oct; 12(8):665-76. PubMed ID: 17269845
[TBL] [Abstract][Full Text] [Related]
14. Trends in Prices, Market Share, and Spending on Self-administered Disease-Modifying Therapies for Multiple Sclerosis in Medicare Part D.
San-Juan-Rodriguez A; Good CB; Heyman RA; Parekh N; Shrank WH; Hernandez I
JAMA Neurol; 2019 Nov; 76(11):1386-1390. PubMed ID: 31449293
[TBL] [Abstract][Full Text] [Related]
15. Opioid drug utilization and cost outcomes associated with the use of buprenorphine-naloxone in patients with a history of prescription opioid use.
Kaur AD; McQueen A; Jan S
J Manag Care Pharm; 2008 Mar; 14(2):186-94. PubMed ID: 18331120
[TBL] [Abstract][Full Text] [Related]
16. Dalfampridine prior authorization program: a cohort study.
Gleason PP; Phillips J; Fenrick BA; Delgado-Riley A; Starner CI
J Manag Care Pharm; 2013; 19(1):18-25. PubMed ID: 23383704
[TBL] [Abstract][Full Text] [Related]
17. The use of disease-modifying agents among multiple sclerosis patients enrolled in medicare from 1995 to 2002 and the impact of medicare part D: analysis of claims data from the medicare current beneficiary survey.
Lundy J; Craig BM
Clin Ther; 2006 Jan; 28(1):140-5. PubMed ID: 16490588
[TBL] [Abstract][Full Text] [Related]
18. Rosiglitazone and pioglitazone utilization from January 2007 through May 2008 associated with five risk-warning events.
Starner CI; Schafer JA; Heaton AH; Gleason PP
J Manag Care Pharm; 2008; 14(6):523-31. PubMed ID: 18693776
[TBL] [Abstract][Full Text] [Related]
19. Generic drug discount programs: are prescriptions being submitted for pharmacy benefit adjudication?
Tungol A; Starner CI; Gunderson BW; Schafer JA; Qiu Y; Gleason PP
J Manag Care Pharm; 2012; 18(9):690-700. PubMed ID: 23206212
[TBL] [Abstract][Full Text] [Related]
20. Cost-Effectiveness of Peginterferon Beta-1a and Alemtuzumab in Relapsing-Remitting Multiple Sclerosis.
Dashputre AA; Kamal KM; Pawar G
J Manag Care Spec Pharm; 2017 Jun; 23(6):666-676. PubMed ID: 28530523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
